{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,6,11]],"date-time":"2023-06-11T05:10:29Z","timestamp":1686460229282},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Drug resistance testing before initiation of, or during, antiretroviral therapy (ART) is not routinely performed in resource-limited settings. High levels of viral resistance circulating within the population will have impact on treatment programs by increasing the chances of transmission of resistant strains and treatment failure. Here, we investigate Drug Resistance Mutations (DRMs) from blood samples obtained at regular intervals from patients on ART (Baseline-22 months) in Karonga District, Malawi. One hundred and forty nine reverse transcriptase (RT) consensus sequences were obtained via nested PCR and automated sequencing from blood samples collected at three-month intervals from 75 HIV-1 subtype C infected individuals in the ART programme.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Fifteen individuals showed DRMs, and in ten individuals DRMs were seen from baseline samples (reported to be ART na\u00efve). Three individuals in whom no DRMs were observed at baseline showed the emergence of DRMs during ART exposure. Four individuals who did show DRMs at baseline showed additional DRMs at subsequent time points, while two individuals showed evidence of DRMs at baseline and either no DRMs, or different DRMs, at later timepoints. Three individuals had immune failure but none appeared to be failing clinically.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Despite the presence of DRMs to drugs included in the current regimen in some individuals, and immune failure in three, no signs of clinical failure were seen during this study. This cohort will continue to be monitored as part of the Karonga Prevention Study so that the long-term impact of these mutations can be assessed. Documenting proviral population is also important in monitoring the emergence of drug resistance as selective pressure provided by ART compromises the current plasma population, archived viruses can re-emerge<\/jats:p><\/jats:sec>","DOI":"10.1186\/1742-6405-8-38","type":"journal-article","created":{"date-parts":[[2011,11,15]],"date-time":"2011-11-15T23:20:40Z","timestamp":1321399240000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Reverse transcriptase drug resistance mutations in HIV-1 subtype C infected patients on ART in Karonga District, Malawi"],"prefix":"10.1186","volume":"8","author":[{"given":"Vijay B","family":"Bansode","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon AA","family":"Travers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amelia C","family":"Crampin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bagrey","family":"Ngwira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil","family":"French","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith R","family":"Glynn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace P","family":"McCormack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,10,13]]},"reference":[{"key":"214_CR1","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1177\/135965350801300502","volume":"13","author":"RL Hamers","year":"2008","unstructured":"Hamers RL, Derdelinckx I, van Vugt M, Stevens W, Rinke de Wit TF, Schuurman R: The status of HIV-1 resistance to antiretroviral drugs in sub-Saharan Africa. Antivir Ther. 2008, 13: 625-639.","journal-title":"Antivir Ther"},{"issue":"Suppl 2","key":"214_CR2","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/135965350801302S13","volume":"13","author":"RW Shafer","year":"2008","unstructured":"Shafer RW, Rhee SY, Bennett DE: Consensus drug resistance mutations for epidemiological surveillance: basic principles and potential controversies. Antivir Ther. 2008, 13 (Suppl 2): 59-68.","journal-title":"Antivir Ther"},{"key":"214_CR3","doi-asserted-by":"publisher","first-page":"e57","DOI":"10.1097\/INF.0b013e3181e47609","volume":"29","author":"RK Gupta","year":"2010","unstructured":"Gupta RK, Ford D, Mulenga V, Walker AS, Kabamba D, Kalumbi M: Drug resistance in human immunodeficiency virus type-1 infected Zambian children using adult fixed dose combination stavudine, lamivudine, and nevirapine. Pediatr Infect Dis J. 2010, 29: e57-62. 10.1097\/INF.0b013e3181e47609","journal-title":"Pediatr Infect Dis J"},{"key":"214_CR4","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1086\/648444","volume":"49","author":"CJ Hoffmann","year":"2009","unstructured":"Hoffmann CJ, Charalambous S, Sim J, Ledwaba J, Schwikkard G, Chaisson RE: Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa. Clin Infect Dis. 2009, 49: 1928-1935. 10.1086\/648444","journal-title":"Clin Infect Dis"},{"key":"214_CR5","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/jmv.21677","volume":"82","author":"ST Burda","year":"2010","unstructured":"Burda ST, Viswanath R, Zhao J, Kinge T, Anyangwe C, Tinyami ET: HIV-1 reverse transcriptase drug-resistance mutations in chronically infected individuals receiving or naive to HAART in Cameroon. J Med Virol. 2010, 82: 187-196. 10.1002\/jmv.21677","journal-title":"J Med Virol"},{"key":"214_CR6","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1742-6405-6-12","volume":"6","author":"K Steegen","year":"2009","unstructured":"Steegen K, Luchters S, Dauwe K, Reynaerts J, Mandaliya K, Jaoko W: Effectiveness of antiretroviral therapy and development of drug resistance in HIV-1 infected patients in Mombasa, Kenya. AIDS Res Ther. 2009, 6: 12- 10.1186\/1742-6405-6-12","journal-title":"AIDS Res Ther"},{"issue":"Suppl 3","key":"214_CR7","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1097\/00002030-200317003-00006","volume":"17","author":"PJ Weidle","year":"2003","unstructured":"Weidle PJ, Downing R, Sozi C, Mwebaze R, Rukundo G, Malamba S: Development of phenotypic and genotypic resistance to antiretroviral therapy in the UNAIDS HIV Drug Access Initiative--Uganda. Aids. 2003, 17 (Suppl 3): S39-48.","journal-title":"Aids"},{"key":"214_CR8","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1089\/aid.2010.0203","volume":"27","author":"V Bansode","year":"2011","unstructured":"Bansode V, Drebert ZJ, Travers SA, Banda E, Molesworth A, Crampin A: Drug Resistance Mutations in Drug-Naive HIV Type 1 Subtype C-Infected Individuals from Rural Malawi. AIDS Res Hum Retroviruses. 2011, 27: 439-444. 10.1089\/aid.2010.0203","journal-title":"AIDS Res Hum Retroviruses"},{"key":"214_CR9","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1097\/QAD.0b013e32832ac34e","volume":"23","author":"MC Hosseinipour","year":"2009","unstructured":"Hosseinipour MC, van Oosterhout JJ, Weigel R, Phiri S, Kamwendo D, Parkin N: The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. Aids. 2009, 23: 1127-1134. 10.1097\/QAD.0b013e32832ac34e","journal-title":"Aids"},{"key":"214_CR10","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1089\/aid.2009.0164","volume":"26","author":"WI Towler","year":"2010","unstructured":"Towler WI, Barlow-Mosha L, Church JD, Bagenda D, Ajuna P, Mubiru M: Analysis of drug resistance in children receiving antiretroviral therapy for treatment of HIV-1 infection in Uganda. AIDS Res Hum Retroviruses. 2010, 26: 563-568. 10.1089\/aid.2009.0164","journal-title":"AIDS Res Hum Retroviruses"},{"key":"214_CR11","volume-title":"Quarterly HIV Programme Report of HIV testing and counseling, Prevention of Mother to Child Transmission, Antiretroviral Therapy, Treatment of Sexually Transmitted Infections with results upto June 2010","author":"Ministry of Health GoM","year":"2010","unstructured":"Ministry of Health GoM: Quarterly HIV Programme Report of HIV testing and counseling, Prevention of Mother to Child Transmission, Antiretroviral Therapy, Treatment of Sexually Transmitted Infections with results upto June 2010. 2010"},{"key":"214_CR12","doi-asserted-by":"publisher","first-page":"12890","DOI":"10.1128\/JVI.76.24.12890-12899.2002","volume":"76","author":"GP McCormack","year":"2002","unstructured":"McCormack GP, Glynn JR, Crampin AC, Sibande F, Mulawa D, Bliss L: Early evolution of the human immunodeficiency virus type 1 subtype C epidemic in rural Malawi. J Virol. 2002, 76: 12890-12899. 10.1128\/JVI.76.24.12890-12899.2002","journal-title":"J Virol"},{"key":"214_CR13","volume-title":"AIDS Res Hum Retroviruses","author":"V Bansode","year":"2010","unstructured":"Bansode V, Drebert ZJ, Travers SA, Banda E, Molesworth A, Crampin A: Drug Resistance Mutations in Drug-Naive HIV Type 1 Subtype C-Infected Individuals from Rural Malawi. AIDS Res Hum Retroviruses. 2010"},{"key":"214_CR14","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1093\/nar\/gkg100","volume":"31","author":"SY Rhee","year":"2003","unstructured":"Rhee SY, Gonzales MJ, Kantor R, Betts BJ, Ravela J, Shafer RW: Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res. 2003, 31: 298-303. 10.1093\/nar\/gkg100","journal-title":"Nucleic Acids Res"},{"key":"214_CR15","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1093\/bioinformatics\/btl446","volume":"22","author":"A Stamatakis","year":"2006","unstructured":"Stamatakis A: RAxML-VI-HPC: maximum likelihood-based phylogenetic analyses with thousands of taxa and mixed models. Bioinformatics. 2006, 22: 2688-2690. 10.1093\/bioinformatics\/btl446","journal-title":"Bioinformatics"},{"key":"214_CR16","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1097\/QAD.0b013e3281c615da","volume":"21","author":"C Seyler","year":"2007","unstructured":"Seyler C, Adje-Toure C, Messou E, Dakoury-Dogbo N, Rouet F, Gabillard D: Impact of genotypic drug resistance mutations on clinical and immunological outcomes in HIV-infected adults on HAART in West Africa. Aids. 2007, 21: 1157-1164. 10.1097\/QAD.0b013e3281c615da","journal-title":"Aids"},{"key":"214_CR17","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/00126334-200501010-00003","volume":"38","author":"C Laurent","year":"2005","unstructured":"Laurent C, Ngom Gueye NF, Ndour CT, Gueye PM, Diouf M, Diakhate N: Long-term benefits of highly active antiretroviral therapy in Senegalese HIV-1-infected adults. J Acquir Immune Defic Syndr. 2005, 38: 14-17. 10.1097\/00126334-200501010-00003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"214_CR18","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/1471-2334-9-108","volume":"9","author":"A Johannessen","year":"2009","unstructured":"Johannessen A, Naman E, Kivuyo SL, Kasubi MJ, Holberg-Petersen M, Matee MI: Virological efficacy and emergence of drug resistance in adults on antiretroviral treatment in rural Tanzania. BMC Infect Dis. 2009, 9: 108- 10.1186\/1471-2334-9-108","journal-title":"BMC Infect Dis"},{"key":"214_CR19","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1089\/088922202753747950","volume":"18","author":"C Pillay","year":"2002","unstructured":"Pillay C, Bredell H, McIntyre J, Gray G, Morris L: HIV-1 subtype C reverse transcriptase sequences from drug-naive pregnant women in South Africa. AIDS Res Hum Retroviruses. 2002, 18: 605-610. 10.1089\/088922202753747950","journal-title":"AIDS Res Hum Retroviruses"},{"key":"214_CR20","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1089\/aid.2005.21.799","volume":"21","author":"LA Petch","year":"2005","unstructured":"Petch LA, Hoffman IF, Jere CS, Kazembe PN, Martinson FE, Chilongozi D: Genotypic analysis of the protease and reverse transcriptase of HIV type 1 subtype C isolates from antiretroviral drug-naive adults in Malawi. AIDS Res Hum Retroviruses. 2005, 21: 799-805. 10.1089\/aid.2005.21.799","journal-title":"AIDS Res Hum Retroviruses"},{"key":"214_CR21","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1089\/088922203762688667","volume":"19","author":"R Handema","year":"2003","unstructured":"Handema R, Terunuma H, Kasolo F, Kasai H, Sichone M, Yamashita A: Prevalence of drug-resistance-associated mutations in antiretroviral drug-naive Zambians infected with subtype C HIV-1. AIDS Res Hum Retroviruses. 2003, 19: 151-160. 10.1089\/088922203762688667","journal-title":"AIDS Res Hum Retroviruses"},{"key":"214_CR22","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1089\/088922202320935483","volume":"18","author":"R Kantor","year":"2002","unstructured":"Kantor R, Zijenah LS, Shafer RW, Mutetwa S, Johnston E, Lloyd R: HIV-1 subtype C reverse transcriptase and protease genotypes in Zimbabwean patients failing antiretroviral therapy. AIDS Res Hum Retroviruses. 2002, 18: 1407-1413. 10.1089\/088922202320935483","journal-title":"AIDS Res Hum Retroviruses"},{"key":"214_CR23","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/135965350701200210","volume":"12","author":"M Zaccarelli","year":"2007","unstructured":"Zaccarelli M, Tozzi V, Lorenzini P, Forbici F, Narciso P, Ceccherini-Silberstein F: The V118I mutation as a marker of advanced HIV infection and disease progression. Antivir Ther. 2007, 12: 163-168.","journal-title":"Antivir Ther"},{"key":"214_CR24","doi-asserted-by":"publisher","first-page":"e4724","DOI":"10.1371\/journal.pone.0004724","volume":"4","author":"DE Bennett","year":"2009","unstructured":"Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M: Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One. 2009, 4: e4724- 10.1371\/journal.pone.0004724","journal-title":"PLoS One"},{"key":"214_CR25","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/QAD.0b013e328011e691","volume":"21","author":"RW Shafer","year":"2007","unstructured":"Shafer RW, Rhee SY, Pillay D, Miller V, Sandstrom P, Schapiro JM: HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. Aids. 2007, 21: 215-223. 10.1097\/QAD.0b013e328011e691","journal-title":"Aids"},{"key":"214_CR26","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jcv.2005.01.005","volume":"34","author":"S Boucher","year":"2005","unstructured":"Boucher S, Recordon-Pinson P, Neau D, Ragnaud JM, Titier K, Faure M: Clonal analysis of HIV-1 variants in proviral DNA during treatment interruption in patients with multiple therapy failures. J Clin Virol. 2005, 34: 288-294. 10.1016\/j.jcv.2005.01.005","journal-title":"J Clin Virol"},{"key":"214_CR27","doi-asserted-by":"publisher","first-page":"16725","DOI":"10.1073\/pnas.0804192105","volume":"105","author":"B Joos","year":"2008","unstructured":"Joos B, Fischer M, Kuster H, Pillai SK, Wong JK, Boni J: HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proc Natl Acad Sci USA. 2008, 105: 16725-16730. 10.1073\/pnas.0804192105","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1742-6405-8-38.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,11]],"date-time":"2023-06-11T04:28:04Z","timestamp":1686457684000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/1742-6405-8-38"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,13]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["214"],"URL":"https:\/\/doi.org\/10.1186\/1742-6405-8-38","relation":{},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,13]]},"assertion":[{"value":"22 June 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"38"}}